Physician profile
Jayson Hymes
NPI 1225032048
$2,504.84
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $1,395 · 2020: $466 · 2021: $544 · 2022: $100.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $1,197.06 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $393.14 | 2019-2021 | |
| Medtronic, INC. | $161.92 | 2021 | |
| Amgen INC. | $152.14 | 2020-2021 | |
| Trice Medical, INC. | $150.85 | 2019 | |
| Alkermes, INC. | $127.67 | 2021-2022 | |
| Pfizer INC. | $122.02 | 2019-2021 | |
| Tersera Therapeutics LLC | $53.88 | 2019 | |
| Daiichi Sankyo INC. | $44.30 | 2019 | |
| Almatica Pharma LLC | $32.74 | 2021 | |
| Biogen, INC. | $29.65 | 2021 | |
| Alexion Pharmaceuticals, INC. | $23.52 | 2019 | |
| Abbott Laboratories | $15.95 | 2019 |
Research and ownership
$820.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayson Hymes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.